Cargando…
Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant
Direct-acting oral anticoagulants (DOACs) represent the standard for preventing stroke and systemic embolization (SSE) in patients with atrial fibrillation (AF). There is limited information for patients ≥ 80 years. We report a retrospective analysis of AF patients ≥ 80 years prescribed either a US...
Autores principales: | Taoutel, Roy, Ezekowitz, Michael D., Chaudhry, Usman A., Weber, Carly, Hassan, Dana, Gracely, Ed J., Kamareddine, Mohammed H., Horn, Benjamin I., Harper, Glenn R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556913/ https://www.ncbi.nlm.nih.gov/pubmed/36246771 http://dx.doi.org/10.1016/j.ijcha.2022.101130 |
Ejemplares similares
-
Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016) -
Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
por: Young, John, et al.
Publicado: (2021) -
FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016) -
Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)